A clinically relevant dilemma arises—if IDH mutations in gliomas are associated with favorable prognosis and prolonged survival, how can vorasidenib—a drug that inhibits effects of these mutations—further improve therapeutic outcomes? The gene discussed is IDH2; the disease is central nervous system cancer.